Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2018 3
2019 4
2020 8
2021 8
2022 8
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean nicolas delannoy (8 results)?
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C, Pérez-Fidalgo JA, Yunokawa M, Dahlstrand H, D'Hondt V, Randall LM; ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators. Oaknin A, et al. Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-6736(23)02405-4. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048793 Clinical Trial.
Nephrotoxicity Associated With Niraparib.
Lazareth H, Delanoy N, Cohen R, Boissier E, Ayari H, Combe P, Crespel C, Mercadier-Riaz E, Karras A, Courbebaisse M, Thervet E, Pallet N. Lazareth H, et al. Among authors: delanoy n. Am J Kidney Dis. 2020 Dec;76(6):898-900. doi: 10.1053/j.ajkd.2020.05.021. Epub 2020 Jul 14. Am J Kidney Dis. 2020. PMID: 32679152 No abstract available.
Real-world dostarlimab use in advanced/recurrent endometrial cancer in France.
Rodrigues M, Eberst L, Follana P, Gauthier L, Jacquemin V, Tessier C, El Mouaddin N, Boudier P, Fiteni F, Angeli E, Roche S, Delanoy N, Sabatier R, Flippot R, de la Motte Rouge T. Rodrigues M, et al. Among authors: delanoy n. Bull Cancer. 2023 Oct;110(10):1041-1050. doi: 10.1016/j.bulcan.2023.06.009. Epub 2023 Aug 31. Bull Cancer. 2023. PMID: 37659907 Free article.
[Place of PARP inhibitors in the treatment of endometrial and cervical cancers].
Le Gac M, Koual M, Delanoy N, Perkins G, Nguyen-Xuan HT, Blons H, Le Frère-Belda MA, Laurent-Puig P, Bentivegna E, Durdux C, Azaïs H, Bats AS. Le Gac M, et al. Among authors: delanoy n. Bull Cancer. 2022 Jan;109(1):65-75. doi: 10.1016/j.bulcan.2021.09.011. Epub 2021 Nov 17. Bull Cancer. 2022. PMID: 34801228 Review. French.
[Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications].
Koual M, Perkins G, Delanoy N, Crespel C, Medioni J, Nguyen-Xuan HT, Douay-Hauser N, Blons H, Le Frère-Belda MA, Molière D, Achen G, Nos C, Balaya V, Montero R, Laurent-Puig P, Bats AS. Koual M, et al. Among authors: delanoy n. Ann Pathol. 2020 Apr;40(2):70-77. doi: 10.1016/j.annpat.2020.01.004. Epub 2020 Feb 8. Ann Pathol. 2020. PMID: 32046878 Review. French.
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Ferron G, De Rauglaudre G, Becourt S, Delanoy N, Joly F, Lortholary A, You B, Bouchaert P, Malaurie E, Gouy S, Kaminsky MC, Meunier J, Alexandre J, Berton D, Dohollou N, Dubot C, Floquet A, Favier L, Venat-Bouvet L, Fabbro M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Desauw C, Del Piano F, Leheurteur M, Bonichon-Lamichhane N, Rastkhah M, Follana P, Gantzer J, Ray-Coquard I, Pujade-Lauraine E. Ferron G, et al. Among authors: delanoy n. Gynecol Oncol. 2023 Mar;170:186-194. doi: 10.1016/j.ygyno.2023.01.008. Epub 2023 Jan 25. Gynecol Oncol. 2023. PMID: 36706645 Clinical Trial.
Prognostic impact of cytoreductive surgery conducted with primary intent, versus cytoreductive surgery after neoadjuvant chemotherapy, in the management of patients with advanced epithelial ovarian cancers: a multicentre, propensity score-matched study from the FRANCOGYN group.
Wohrer H, Koual M, Bentivegna E, Benoit L, Metairie M, Bolze PA, Kerbage Y, Raimond E, Akladios C, Carcopino X, Canlorbe G, Uzan J, Lavoue V, Mimoun C, Huchon C, Koskas M, Costaz H, Margueritte F, Dabi Y, Touboul C, Bendifallah S, Ouldamer L, Delanoy N, Nguyen-Xuan HT, Bats AS, Azaïs H. Wohrer H, et al. Among authors: delanoy n. BJOG. 2023 Nov;130(12):1511-1520. doi: 10.1111/1471-0528.17524. Epub 2023 May 11. BJOG. 2023. PMID: 37165717
33 results